Dose-Response Relationships in Low-Dose Ketamine Therapy

Introduction to Ketamine Dose-Response Pharmacology

Understanding the dose-response relationship of ketamine is essential for clinicians seeking to optimize therapeutic outcomes while minimizing adverse effects. Unlike many pharmacological agents that follow a straightforward sigmoidal dose-response curve, ketamine exhibits a complex, indication-dependent relationship between dose and clinical effect. At subanesthetic concentrations, ketamine primarily acts as an N-methyl-D-aspartate (NMDA) receptor antagonist, but its pharmacological profile extends to opioid receptors, monoaminergic transporters, and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, each with distinct affinity thresholds.

The term "low-dose" ketamine generally refers to doses at or below 0.5 mg/kg administered intravenously, though this boundary shifts depending on the route of administration and the target indication. Clinicians must appreciate that the dose producing antidepressant effects is not identical to the dose producing optimal analgesia, and both differ from the dose at which dissociative side effects begin to emerge.

Dose-Response in Treatment-Resistant Depression

The landmark studies establishing ketamine as a rapid-acting antidepressant used a standardized intravenous dose of 0.5 mg/kg infused over 40 minutes. This dose was selected based on early phase work and has remained the most widely studied protocol. Response rates at this dose typically range from 50 to 70 percent within 24 hours of a single infusion, as measured by validated instruments such as the Montgomery-Asberg Depression Rating Scale (MADRS).

Dose-finding studies have explored whether lower or higher doses produce comparable or superior effects. Research suggests that doses below 0.1 mg/kg produce minimal antidepressant benefit, while doses in the range of 0.1 to 0.3 mg/kg show intermediate efficacy. Importantly, increasing the dose above 0.5 mg/kg does not appear to yield additional antidepressant benefit for most patients but does increase the burden of dissociative and hemodynamic side effects. This suggests a ceiling effect for the antidepressant indication, with the therapeutic window bounded by a minimum effective dose near 0.1 mg/kg and a practical upper limit near 0.5 mg/kg intravenously.

Some emerging evidence points to individual variability in the dose-response curve, potentially influenced by body composition, CYP2B6 and CYP3A4 metabolic phenotype, prior ketamine exposure, and the severity of the depressive episode. For a detailed treatment of ketamine's metabolic pathways, see the pharmacokinetics overview. Personalized dosing strategies based on plasma ketamine or norketamine levels remain an active area of investigation.

Dose-Response in Acute and Chronic Pain

For acute pain management, low-dose ketamine serves as an adjunctive analgesic that reduces opioid consumption and may attenuate opioid-induced hyperalgesia. The dose-response relationship for analgesia follows a more linear pattern at low concentrations compared to the antidepressant effect. Bolus doses of 0.1 to 0.35 mg/kg intravenously provide meaningful analgesic benefit in perioperative and emergency department settings, with effect sizes that increase in a dose-dependent fashion up to approximately 0.35 mg/kg.

Continuous infusions for acute pain typically range from 0.1 to 0.3 mg/kg/hour. Below 0.1 mg/kg/hour, analgesic benefit is often clinically negligible for moderate to severe pain. Above 0.3 mg/kg/hour, the incremental analgesic gain diminishes while psychotomimetic effects become more prominent.

In chronic pain syndromes, particularly those with a neuropathic component such as complex regional pain syndrome (CRPS), higher cumulative doses are often employed over multi-day infusion protocols. Some centers use escalating dose regimens up to 0.5 mg/kg/hour or even higher, though these approach subanesthetic thresholds and require enhanced monitoring. The dose-response relationship in chronic pain is further complicated by central sensitization phenomena and the potential for ketamine to modulate wind-up and long-term potentiation at dorsal horn synapses.

Threshold Doses and the Dissociative Boundary

A critical concept in low-dose ketamine therapeutics is the dissociative threshold. Dissociative symptoms typically emerge at plasma concentrations above 100 to 150 ng/mL, which corresponds roughly to intravenous bolus doses exceeding 0.3 mg/kg or infusion rates above 0.4 mg/kg/hour in most patients. The therapeutic window for both antidepressant and analgesic indications lies largely below this dissociative threshold, though some patients experience mild perceptual changes even at lower doses.

The relationship between dissociation and therapeutic efficacy remains debated. Some investigators have proposed that the dissociative experience itself mediates antidepressant benefit through psychological mechanisms, while others argue that dissociation is merely a side effect unrelated to the molecular mechanism of action. Dose-response studies that carefully titrate to sub-dissociative levels while measuring clinical outcomes are needed to resolve this question.

Clinical Implications for Dose Selection

Clinicians should approach ketamine dosing with an understanding that the optimal dose is indication-specific, patient-specific, and route-dependent. Starting at the lower end of the therapeutic range and titrating upward based on clinical response and tolerability is a prudent strategy. Monitoring tools such as the Clinician-Administered Dissociative States Scale (CADSS) and serial vital sign assessments provide objective data to guide dose adjustments. As the evidence base matures, pharmacogenomic profiling and therapeutic drug monitoring may further refine individualized dosing protocols, moving the field from empiric dosing toward precision ketamine therapeutics.

References

• PubMed: Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics — Comprehensive review of ketamine dose-response relationships, pharmacokinetics, and clinical pharmacodynamics
• DailyMed: FDA Drug Label Information — National Library of Medicine database for official FDA drug labeling including approved dose ranges
• PubChem: Ketamine Compound Summary — NCBI PubChem database entry for ketamine receptor binding affinities and pharmacological data
• MedlinePlus: Ketamine Injection Drug Information — National Library of Medicine patient medication information for ketamine dosing